Payment & Shipping Terms:
|Other Name:||Mk2866||CAS register number:||841205-47-8|
|Molecular formula:||C19H14F3N3O3||Molecular weight:||389.33|
MK2866 Raw Material Powder,
SARM Raw Material Powder
|Packing||1kg net/foil bag, 5kg/drum.|
|Storage||Shading , Confined Preservation|
|Usage||Increasing lean mass gains
Enhancement for strength
Joint healing abilities
MK 2866 description :
1. Ostarine (MK-2866) is a SARM developed by GTx for the prevention and treatment of muscle wasting. It may eventually be a medical prescription for the prevention of cachexia, atrophy and sarcopenia as well as for Hormone or Testosterone Replacement Therapy.
2. As a research chemical, Ostarine belongs to a class of chemicals know as SARMS or selective androgen receptor modulators. SARMS create selective anabolic activity at certain androgen receptors.
3.In comparison to testosterone and other anabolic steroids, the advantage of SARMS, is they do not have androgenic activity in non-skeletal muscle tissues. Ostarine is effective in maintaining and increasing lean body mass.
MK 2866 Usage:
(1) For Bulking
Shines best when used for gaining lean muscle (bulking) as it is the most anabolic of all the SARMS. Suggested dosage is 25 mg for 4-6 weeks. PCT is not necessary. An increase of 6 lbs. of lean, keepable gains can be observed during this period
You can take Ostarine as high as 36 mg for 8 weeks BUT only if you weigh 210 lbs. Suppression is expected in higher doses so PCT after a cycle is a must.
(2) For Recomping
Ostarine shines in recomping due to its nutrient portioning results. Calorie is used to build muscle which helps in weight loss and enhancing muscle mass and strength. Suggested dosing is 12.5-25 mg for 4-8 weeks.
Your diet must contain 30% of lean sources of protein to achieve the best recomp result.
(3) For Cutting
MK-2866 can help cut whilst preserving muscle gains and decreasing calories. Suggested dosing is 12.5-15 mg for 4-6 weeks.
|RAD140||1182367-47-0||New generation for gaining mass and cutting edges|
|Andarine(S4)||401900-40-0||partial agonist, intended mainly for treatment of benign prostatic hypertrophy|
|LGD-4033||1165910-22-4||pharmacological profile similar to that of enobosarm, Ostarine,MK-2866|
|GW1516||317318-70-0||For obesity, diabetes, dyslipidemia and cardiovascular disease|
|YK11||431579-34-9||YK11: a SARM and myostatin inhibitor in one|
Contact Person: Gavin Lee